Dr. Sareena Singh
Claim this profileAultman Health Foundation
Studies Endometrioid Carcinoma
Studies Adenocarcinoma
8 reported clinical trials
17 drugs studied
Area of expertise
1Endometrioid Carcinoma
Stage IV
MMR negative
BRCA1 positive
2Adenocarcinoma
Stage IV
BRCA1 positive
BRCA2 positive
Affiliated Hospitals
Clinical Trials Sareena Singh is currently running
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
Recruiting1 award Phase 2 & 3
Surgical Procedures
for Reducing Ovarian Cancer Risk
This study evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Recruiting1 award N/A
More about Sareena Singh
Clinical Trial Related5 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sareena Singh has experience with
- Pembrolizumab
- Olaparib
- Cediranib Maleate
- Durvalumab
- Carboplatin
- Paclitaxel
Breakdown of trials Sareena Singh has run
Endometrioid Carcinoma
Adenocarcinoma
Cancer
Serous Cystadenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sareena Singh specialize in?
Sareena Singh focuses on Endometrioid Carcinoma and Adenocarcinoma. In particular, much of their work with Endometrioid Carcinoma has involved Stage IV patients, or patients who are MMR negative.
Is Sareena Singh currently recruiting for clinical trials?
Yes, Sareena Singh is currently recruiting for 2 clinical trials in Canton Ohio. If you're interested in participating, you should apply.
Are there any treatments that Sareena Singh has studied deeply?
Yes, Sareena Singh has studied treatments such as Pembrolizumab, Olaparib, Cediranib Maleate.
What is the best way to schedule an appointment with Sareena Singh?
Apply for one of the trials that Sareena Singh is conducting.
What is the office address of Sareena Singh?
The office of Sareena Singh is located at: Aultman Health Foundation, Canton, Ohio 44710 United States. This is the address for their practice at the Aultman Health Foundation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.